Long-Term Progression-Free Survival With Sunitinib in Advanced Recurrent Adrenocortical Carcinoma [0.03%]
舒尼替尼治疗晚期复发性肾上腺皮质癌的长期无进展生存期研究
Ali Turker,Mahmut Buyuksimsek,İrem Kolsuz Turker et al.
Ali Turker et al.
Everolimus and Sunitinib potentially work as therapeutic drugs for infantile hemangiomas [0.03%]
埃维莫司和索拉非尼有望成为婴幼儿血管瘤治疗药物
Rongfang Xie,Zhujue Taohuang,Rosalind Kieran et al.
Rongfang Xie et al.
Background: Infantile hemangiomas (IH) are common vascular tumors in infants, with no well-defined therapeutic agents currently available. Recent studies have explored molecular mechanisms involved in IH progression, but ...
Sheng Zhang,Mingjuan Sun,Qin Wang et al.
Sheng Zhang et al.
Alexander D Sherry,Ethan B Ludmir,Pavlos Msaouel
Alexander D Sherry
First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern Asia [0.03%]
一线帕博利珠单抗-阿昔替尼与舒尼替尼治疗转移性肾细胞癌：来自KEYNOTE-426三期临床试验的东亚人群亚组分析结果
Hsiao-Jen Chung,Chihiro Kondoh,Woo Kyun Bae et al.
Hsiao-Jen Chung et al.
Background: The phase 3 open-label KEYNOTE-426 study demonstrated that first-line pembrolizumab plus axitinib improved overall survival (OS) and progression-free survival (PFS) versus sunitinib for metastatic renal cell c...
First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study [0.03%]
一线基于免疫的联合治疗或舒尼替尼治疗有利风险转移性肾细胞癌：ARON-1研究的事后回顾比较
Giandomenico Roviello,Javier Molina-Cerrillo,Francesco Massari et al.
Giandomenico Roviello et al.
Introduction: Renal cell carcinoma (RCC) is one of the most common types of urogenital cancer. The introduction of immune-based combinations, including dual immune-checkpoint inhibitors (ICI) or ICI plus tyrosine kinase i...
Comparative Study
Cancer immunology, immunotherapy : CII. 2025 Jan 3;74(2):65. DOI:10.1007/s00262-024-03897-x 2025
Biomarker analyses from the phase 3 randomized CLEAR trial: Lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma [0.03%]
CLEAR研究的生物标志物分析：仑伐替尼联合帕博利珠单抗对比舒尼替尼治疗晚期肾细胞癌三期随机试验
R J Motzer,C Porta,M Eto et al.
R J Motzer et al.
Background: In CLEAR, lenvatinib + pembrolizumab (L+P) significantly improved efficacy versus sunitinib in first-line treatment of patients with advanced renal cell carcinoma (RCC). We report results from CLEAR biomarker ...
First-line sunitinib treatment modification in patients with mRCC: nationwide analysis of the Swedish population [0.03%]
瑞典全国转移性肾细胞癌一线舒尼替尼治疗人群的调整治疗分析研究
Maria Jakobsson,Fredrik Nilsson,Angela Strambi et al.
Maria Jakobsson et al.
Aim: Assess first-line sunitinib dosing for treatment of metastatic renal cell carcinoma in Swedish clinical practice (2006-2019).Materials & methods: Retrospective analysis of three sunitinib dosing regimens: 2-weeks on, 1-week off (2:1 St...
Prediction of the response to antiangiogenic sunitinib therapy by non-invasive hybrid diffuse optics in renal cell carcinoma [0.03%]
非侵入性杂交扩散光学预测肾细胞癌索拉非尼抗血管生成治疗的反应
Miguel Mireles,Gabriela Jiménez-Valerio,Jordi Morales-Dalmau et al.
Miguel Mireles et al.
In this work, broadband diffuse reflectance spectroscopy (DRS) and diffuse correlation spectroscopy (DCS) were used to quantify deep tissue hemodynamics in a patient-derived orthotopic xenograft mouse model of clear cell renal cancer underg...
Comparative Analysis of Traditional and Pharmacometric-Based Pharmacoeconomic Modeling in the Cost-Utility Evaluation of Sunitinib Therapy [0.03%]
传统方法与药物计量学基于的方法在舒尼替尼治疗成本效用评估中的比较分析
Maddalena Centanni,Janine Nijhuis,Mats O Karlsson et al.
Maddalena Centanni et al.
Background: Cost-utility analyses (CUAs) increasingly use models to predict long-term outcomes and translate trial data to real-world settings. Model structure uncertainty affects these predictions. This study compares ph...
耗时 0.12346 秒，为您在
48229835
条记录里面共找到 604 篇文章 [XML]